SAGE Therapeutics Inc (SAGE) Expected to Announce Earnings of -$2.39 Per Share

Wall Street analysts expect SAGE Therapeutics Inc (NASDAQ:SAGE) to post ($2.39) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for SAGE Therapeutics’ earnings, with estimates ranging from ($2.79) to ($2.02). SAGE Therapeutics reported earnings per share of ($1.97) in the same quarter last year, which indicates a negative year over year growth rate of 21.3%. The company is scheduled to report its next earnings results on Thursday, November 1st.

According to Zacks, analysts expect that SAGE Therapeutics will report full year earnings of ($7.99) per share for the current year, with EPS estimates ranging from ($10.62) to ($6.23). For the next financial year, analysts forecast that the company will post earnings of ($10.47) per share, with EPS estimates ranging from ($21.68) to ($5.06). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow SAGE Therapeutics.

SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.84) by $1.48. The firm had revenue of $90.00 million during the quarter.

A number of equities analysts have commented on the stock. BidaskClub upgraded shares of SAGE Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 14th. Piper Jaffray Companies assumed coverage on shares of SAGE Therapeutics in a research report on Monday, August 6th. They issued an “overweight” rating and a $206.00 price target on the stock. ValuEngine upgraded shares of SAGE Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Canaccord Genuity restated a “buy” rating and issued a $210.00 price target on shares of SAGE Therapeutics in a research report on Thursday, May 3rd. Finally, Cowen restated a “buy” rating and issued a $207.00 price target on shares of SAGE Therapeutics in a research report on Thursday, June 14th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $199.19.

Several hedge funds have recently made changes to their positions in the company. CIBC Asset Management Inc lifted its position in shares of SAGE Therapeutics by 26.4% during the second quarter. CIBC Asset Management Inc now owns 1,633 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 341 shares in the last quarter. Prudential Financial Inc. lifted its position in shares of SAGE Therapeutics by 9.5% during the first quarter. Prudential Financial Inc. now owns 4,220 shares of the biopharmaceutical company’s stock worth $680,000 after purchasing an additional 366 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of SAGE Therapeutics by 3.2% during the first quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock worth $1,998,000 after purchasing an additional 382 shares in the last quarter. Neuberger Berman Group LLC lifted its position in shares of SAGE Therapeutics by 15.3% during the first quarter. Neuberger Berman Group LLC now owns 3,459 shares of the biopharmaceutical company’s stock worth $557,000 after purchasing an additional 459 shares in the last quarter. Finally, Amalgamated Bank lifted its position in shares of SAGE Therapeutics by 9.2% during the first quarter. Amalgamated Bank now owns 5,623 shares of the biopharmaceutical company’s stock worth $906,000 after purchasing an additional 476 shares in the last quarter.

NASDAQ:SAGE opened at $149.74 on Tuesday. The stock has a market capitalization of $6.92 billion, a price-to-earnings ratio of -21.12 and a beta of 2.88. SAGE Therapeutics has a 12 month low of $59.57 and a 12 month high of $195.97.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Further Reading: What is the NASDAQ Stock Market?

Get a free copy of the Zacks research report on SAGE Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply